Contact: John Sterling, 914-740-2196, email@example.com
GEN Reports on Growth of Affinity Proteomics
New Rochelle, NY, May 7, 2012—The field of disease proteomics has, until recently, focused on separation techniques coupled with mass-spectrometric identification of proteins, reports Genetic Engineering & Biotechnology News (GEN). But technological limitations due to patient-to-patient variability and loss of signal from low-abundance proteins have led some investigators to increasingly rely on another method, affinity proteomics, according to a recent issue of GEN.
“Scientists studying biomarkers have found affinity arrays to be particularly useful to their discovery projects,” said John Sterling, Editor in Chief of GEN.
According to researchers, antibody-based proteomics has revealed multiple specific biomarker candidates, many of which are being translated into clinical practice. RayBiotech is one company that specializes in cytokine antibody arrays. The firm’s products are used for probing disease processes, especially when only a few details are known.
The GEN article also covers work taking place on affinity proteomics at Lund University, KTH Royal Institute of Technology, OncoMark, and the German Cancer Research Center.
For a copy of the May 1 issue of GEN, please call (914) 740-2146, or email: firstname.lastname@example.org
Genetic Engineering & Biotechnology News, which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.